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Abstract
Introduction Breast cancer is the leading cause of cancer death
in women worldwide. Elevated expression of c-Myc is a frequent
genetic abnormality seen in this malignancy. For a better
understanding of its role in maintaining the malignant phenotype,
we used RNA interference (RNAi) directed against c-Myc in our
study. RNAi provides a new, reliable method to investigate gene
function and has the potential for gene therapy. The aim of the
study was to examine the anti-tumor effects elicited by a
decrease in the protein level of c-Myc by RNAi and its possible
mechanism of effects in MCF-7 cells.
Method A plasmid-based polymerase III promoter system was
used to deliver and express short interfering RNA (siRNA)
targeting c-myc  to reduce its expression in MCF-7 cells.
Western blot analysis was used to measure the protein level of
c-Myc. We assessed the effects of c-Myc silencing on tumor
growth by a growth curve, by soft agar assay and by nude mice
experiments in vivo. Standard fluorescence-activated cell sorter
analysis and TdT-mediated dUTP nick end labelling assay were
used to determine apoptosis of the cells.
Results Our data showed that plasmids expressing siRNA
against c-myc markedly and durably reduced its expression in
MCF-7 cells by up to 80%, decreased the growth rate of MCF-
7 cells, inhibited colony formation in soft agar and significantly
reduced tumor growth in nude mice. We also found that
depletion of c-Myc in this manner promoted apoptosis of MCF-
7 cells upon serum withdrawal.
Conclusion c-Myc has a pivotal function in the development of
breast cancer. Our data show that decreasing the c-Myc protein
level in MCF-7 cells by RNAi could significantly inhibit tumor
growth both in vitro and  in vivo, and imply the therapeutic
potential of RNAi on the treatment of breast cancer by targeting
overexpression oncogenes such as c-myc, and c-myc might be
a potential therapeutic target for human breast cancer.
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Introduction
Breast cancer is the leading cause of cancer death in
women worldwide. Despite advances in detection and
chemotherapy, many women with breast cancer continue
to die of this malignancy [1]. Therefore, an understanding
of the molecular mechanisms involved in breast cancer for-
mation and progression should be helpful in developing
more effective treatments for breast cancer.
c-Myc is believed to participate in most aspects of cellular
function, including replication, growth, metabolism, differ-
entiation, and apoptosis [2]. Previous studies indicate that
c-Myc activates a variety of known genes as part of a het-
erodimeric complex with Max [2]. A frequent genetic abnor-
mality seen in breast cancer is the elevated expression of c-
Myc [3,4]. The importance of c-Myc expression in breast
cancer is demonstrated both by studies of transgenic mice
and by clinical research [3,5]. Abnormal expression of c-
myc transgenes in the mouse mammary gland is associ-
ated with an increased incidence of breast carcinomas [5].
Moreover, clinical studies have indicated that c-Myc is
important in the development and progression of breast
cancer, in that overexpression of c-Myc was found in most
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breast cancer patients and was correlated with poor prog-
nosis in those patients [3].
The role of c-Myc in breast cancer has been extensively
examined in many studies for the past decade [6]; however,
specifically reducing its level by genetic means in estab-
lished breast cancer cell lines is still helpful for a better
understanding of its role in maintaining the malignant phe-
notype. Thus, in this study, we investigated whether specif-
ically decreasing the protein level of c-Myc in a breast
cancer cell line in which this protein was overexpressed
might result in the inhibition of cell growth in vitro and in
vivo. For this purpose, RNA interference (RNAi) directed
against c-myc was used.
RNAi is the sequence-specific gene silencing induced by
double-stranded RNA (dsRNA). This phenomenon is con-
served in a variety of organisms: Caenorhabditis elegans,
Drosophila, plants, and mammals. RNAi is mediated by
short interfering RNAs (siRNAs) that are produced from
long dsRNAs of exogenous or endogenous origin by an
endonuclease of the ribonuclease-III type, called Dicer. The
resulting siRNAs are about 21–23 nucleotides (nt) long
and are then incorporated into a nuclease complex, the
RNA-inducing silencing complex, which then targets and
cleaves mRNA containing a sequence identical to that of
the siRNA [7]. Rapid progress has been made in the use of
RNAi [8]. More recently, a technical breakthrough came
from the demonstration that dsRNA of 19–29 nt expressed
endogenously with RNA polymerase III promoter induced
target gene silencing in mammalian cells [9]. The expres-
sion of siRNA from DNA templates offers several advan-
tages over chemically synthesized siRNA delivery. Hairpin
siRNAs transcribed from a vector are thought to suppress
the expression of targeted genes more efficiently, less
expensively and more easily than synthesized siRNA [10].
Here we used a plasmid-based polymerase III promoter
system to deliver and express siRNA targeting c-myc to
determine whether this technique could be used for the
specific inhibition of oncogene overexpression and
whether this inhibition resulted in antitumor effects. We
showed in our study that specific downregulation of c-Myc
by RNAi was sufficient to inhibit the growth of MCF-7 cells
in vitro and in vivo, and that c-myc might serve as a thera-
peutic target for human breast cancer.
Method
Plasmid construction
To generate c-Myc knockdown vector, one annealed set of
oligonucleotides encoding short hairpin transcripts corre-
sponding to nt 1906–1926 of c-myc  mRNA (GenBank
accession no. NM-002467) [11] were cloned into pSi-
lencer  1.0_U6 (Ambion; hereafter abbreviated to pSi-
lencer). In brief, the short-hairpin-RNA-encoding
complementary single-stranded oligonucleotides, which
hybridized to give overhangs compatible with ApaI and
EcoRI, were designed with a computer program available
on the Internet http://www.ambion.com/techlib/misc/
psilencer_converter.html. Oligonucleotides encoding short
hairpin RNAs were then ligated into pSilencer. Bacterial
colonies were pooled and used for plasmid preparation.
The positive clones were confirmed by sequencing. The
resulting plasmid was designated as pSilencer–c-Myc.
Cell line and cell culture
The breast cancer adenocarcinoma cell line MCF-7 was
obtained from the American Type Culture Collection (Man-
assas, VA). The cells were grown in Dulbecco's modified
Eagle's medium (Invitrogen) supplemented with 10% fetal
bovine serum (Gibco BRL), 50 units/ml penicillin, and 50
µg/ml streptomycin. The MCF-7 cells were maintained in a
humidified 37°C incubator with 5% CO2, fed every 3 days
with complete medium, and subcultured when confluence
was reached.
Transfection of cells
A total of 2 × 105 cells were seeded into each well of a six-
well tissue culture plate (Costar). The next day (when the
cells were 70–80% confluent), the culture medium was
aspirated and the cell monolayer was washed with pre-
warmed sterile phosphate-buffered saline (PBS). Cells
were transfected with the appropriate plasmids by using
LipofectAMINE reagent (Invitrogen) in accordance with the
manufacturer's protocol. The cells were harvested at differ-
ent time points. Western blot analysis or other experiments
were performed.
Western blot analysis
Cells were harvested at different time points and lysed in
mammalian cell lysis buffer, then western blot analysis was
performed with the use of conventional protocols as
described previously [12]. In brief, the protein concentra-
tion was determined with a bicinchoninic acid kit with
bovine serum albumin as a standard (Pierce). Equal
amounts of total protein were then separated on 12% poly-
acrylamide gels by using standard sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE) tech-
niques, then transferred to nitrocellulose membranes
(PROTRAN). The antibodies and dilutions used included
anti-c-Myc (9E10; 1:1000 dilution; Santa Cruz) and anti-β-
actin (AC-15; 1:5000 dilution; Sigma), and after being
washed extensively the membranes were incubated with
anti-mouse IgG–horseradish peroxidase conjugate anti-
body (Zhongshan Company) for 1 hour at room tempera-
ture and developed with a Luminol chemiluminescence
detection kit (Santa Cruz). Membranes probed for c-Myc
were reprobed for β-actin to normalize for loading and/or
quantification errors and to allow comparisons of target
protein expression to be made. Protein expression wasAvailable online http://breast-cancer-research.com/content/7/2/R220
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quantified with a Gel EDAS analysis system (Cold Spring
USA Corporation) and Gel-Pro Analyzer 3.1 software
(Media Cybernetics).
Cell growth assay
At 2 days after transfection, MCF-7 cells transfected with
indicated plasmids were harvested and replated at a den-
sity of 50 cells/mm2 in triplicate. The total cell number was
quantified every 2 days with a hematocytometer and an
Olympus inverted microscope. Cell viability was assessed
by using trypan blue.
Soft agar colony assay
At 2 days after transfection, MCF-7 cells (300 cells per
well) transfected with indicated plasmids were mixed with
tissue culture medium containing 0.7% agar to result in a
final agar concentration of 0.35%. Then 1 ml samples of
this cell suspension were immediately plated in six-well
plates coated with 0.6% agar in tissue culture medium (2
ml per well) and cultured at 37°C with 5% CO2. After 2
weeks the top layer of the culture was stained with 0.2% p-
iodonitrotetrazolium violet (Sigma). The culture was ana-
lyzed in triplicate, and colonies larger than 100 µm in diam-
eter were counted.
Tumor growth in nude mice
Equal numbers (106 or 2 × 106) of MCF-7 cells transfected
with pSilencer–c-Myc or pSilencer  were harvested by
trypsinization 2 days after transfection, washed twice with
1 × PBS, and resuspended in 0.2 ml of saline. Two groups
of five 4–6-week-old female nude mice were then given
bilateral subcutaneous injections with control cells or cells
transfected with plasmids against c-Myc. The mice were
kept in pathogen-free environments and checked every 2
days. The date at which a palpable tumor first arose and the
weight of the tumor were recorded.
Cell cycle analysis
Standard fluorescence-activated cell sorting analysis was
used to determine apoptosis of the cells. In brief, MCF-7
cells were transfected with pSilencer–c-Myc or pSilencer;
24 hours later, cells were deprived of serum for 36 hours.
Then cells were harvested, washed once in PBS and
stained with propidium iodide (BD Biosciences). The apop-
totic cells were assessed by flow cytometric detection of
sub-G1 DNA content.
TdT-mediated dUTP nick end labelling assay
Apoptotic cells were confirmed with the in situ cell death
detection kit, Alkaline Phosphatase (Roche Applied Sci-
ence), in accordance with the manufacturer's instructions.
In brief, MCF-7 cells were grown on coverslips. The next
day, cells were transfected with pSilencer–c-Myc or pSi-
lencer. At 24 hours after transfection, cells were deprived
of serum for 36 hours. Coverslips with adherent cells were
fixed in 4% paraformaldehyde for 1 hour at room tempera-
ture and permeabilized with 0.1% Triton X-100 for 2 min on
ice. DNA fragments were labeled with the TdT-mediated
dUTP nick end labelling (TUNEL) reaction mixture for 60
min at 37°C in a humidified atmosphere in the dark. The
coverslips were then incubated with Converter alkaline
phosphatase for 30 min at 37°C in a humidified chamber,
rinsed in PBS, and incubated with nitro blue tetrazolium/5-
bromo-4-chloroindol-3-yl phosphate (Roche Applied Sci-
ence) for 10 min. Cells were mounted cell side downward
on a microscope slide, and the apoptotic cells (dark blue
Figure 1
Schematic drawing of the pSilencer1.0_U6 vector Schematic drawing of the pSilencer1.0_U6 vector. The U6-RNA promoter was cloned in front of the gene-specific targeting sequence (19-nucle-
otide sequences from the target transcript separated by a short spacer from the reverse complement of the same sequence) and six thymidines (T6) 
as a termination signal. The predicted secondary structure of the pSilencer–c-Myc transcript target c-Myc is shown. The transcript, a short hairpin 
double-stranded RNA (dsRNA), is believed to be further cleaved by Dicer to generate a 21-nucleotide siRNA that forms dsRNA–endonuclease com-
plexes and will bind and destroy c-myc mRNA.Breast Cancer Research    Vol 7 No 2    Wang et al.
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staining) were counted under a microscope. Three fields
were randomly counted for each sample.
Statistical analysis
SPSS for Windows (SPSS Inc.) was used to analyze the
data and plot curves. A two-tailed unpaired t-test was used
to compare the statistical significance of the differences in
data from the two groups.
Results
Suppression of c-Myc overexpression in MCF-7 cells by 
RNAi
We designed and synthesized one pair of oligonucleotides
encoding short hairpin transcripts directed against a por-
tion of the c-myc mRNA. This pair of oligonucleotides was
then ligated into pSilencer. The plasmid of pSilencer–c-
Myc contains a U6 promoter that directs the synthesis of
oligonucleotides in an inverted repeat with 9 nt for its loop,
with six T bases added at the end to serve as a termination
signal for RNA polymerase III. The RNA is expected to fold
back to form a hairpin loop structure after being tran-
scribed; the hairpin dsRNA can then be further cleaved by
Dicer to generate a 21-nucleotide siRNA, the active form
for the RNAi effect, which will form dsRNA–endonuclease
complexes and will bind and destroy c-myc mRNA inside
cells [8] (Fig. 1).
pSilencer–c-Myc was transfected into MCF-7 cells and its
effects on c-Myc protein levels were determined by com-
parison with pSilencer-transfected cells by western blot at
the time points indicated. We found that the c-Myc expres-
sion levels were suppressed by up to 80% in MCF-7 cells
at day 5 after transfection. Actually the levels of c-Myc were
decreased as early as 24 hours after transfection and
remained at low levels until 12 days after transfection (Fig.
2). The inhibitory effect was shown to be specific because
transfection with pSilencer did not alter c-Myc levels. In
addition, RNAi did not cause a nonspecific downregulation
of gene expression, as determined by the β-actin control
(Fig. 2). Similar results with c-Myc RNAi were also seen in
other cell lines including HCT116 and HepG2 (data not
shown). These data indicated that vector-based RNAi
could effectively suppress c-Myc overexpression and
resulted in prolonged decreases in specific cellular gene
expression without marked effects on other cellular
proteins.
Decreased levels of c-Myc significantly alter the growth 
rate of MCF-7 cells
Previous studies have shown that c-Myc is important in cel-
lular proliferation and cell growth [6]. Thus, increased levels
of c-Myc might have a function in the growth advantage
seen in breast tumors. In our study, MCF-7 cells were trans-
fected with pSilencer–c-Myc or pSilencer. The number of
MCF-7 cells was then counted every 2 days after transfec-
tion. Our data showed that RNAi directed against c-myc
significantly decreased the growth rate of MCF-7 cells, with
a 50–60% decrease at different time points repeatedly in
three separate experiments (Fig. 3).
Decreases in c-Myc protein inhibit colony formation
We then tested whether RNAi-mediated reductions in c-
Myc levels could influence the ability of MCF-7 cells to form
colonies in soft agar. MCF-7 cells were transfected with
pSilencer–c-Myc or pSilencer. At 48 hours after transfec-
tion, the cells were placed into medium with soft agar, and
colonies were counted after 2 weeks. RNAi directed
against c-myc  resulted in a significant decrease (about
65%) in colony formation in MCF-7 cells (Fig. 4). The
smaller number of colonies in the pSilencer–c-Myc group
than in the control group was statistically significant (P <
0.001). These results showed that the reduction in c-Myc
protein level decreased the ability of breast cancer cells to
form colonies in soft agar.
Figure 2
Time course of the reduction in c-Myc protein levels by pSilencer–c- Myc Time course of the reduction in c-Myc protein levels by pSilencer–c-
Myc. Exponentially proliferating MCF-7 cells were transfected with pSi-
lencer–c-Myc or pSilencer and whole cell lysates were prepared at the 
time points indicated. Total cell lysates were separated by SDS–poly-
acrylamide-gel electrophoresis and immunoblotted with an antibody 
against c-Myc; expression levels were normalized for loading by prob-
ing for β-actin.Available online http://breast-cancer-research.com/content/7/2/R220
R224
RNAi directed against c-Myc reduces tumor growth in 
nude mice
To address the potential effects of RNAi in vivo on inhibit-
ing the growth of breast cancer cells, equal numbers (106
or 2 × 106) of MCF-7 cells transfected with pSilencer–c-
Myc or pSilencer were injected into female nude mice (five
animals for each treatment). At 5 or 8 weeks after injection
of these cells, the mice were killed and the weights of the
tumors were recorded. As seen in Table 1, when 106 cells
were injected into nude mice, tumors were seen 8 weeks
later in three of five at the left lateral where MCF-7 cells
transfected with pSilencer were injected, whereas none
were seen at the right lateral where MCF-7 cells trans-
fected with pSilencer–c-Myc were injected. In addition, 5
weeks after 2 × 106 cells were injected into nude mice,
tumors were seen in four of five at the left lateral where
MCF-7 cells transfected with pSilencer  were injected,
whereas none were seen at the right lateral where MCF-7
cells transfected with pSilencer–c-Myc were injected
(Table 1). Thus, c-Myc RNAi significantly suppressed tumor
growth in nude mice in comparison with control, indicating
that targeting c-myc by RNAi could exert a strong antitumor
effect in vivo on MCF-7 cells.
Induction of apoptosis in MCF-7 cells by RNAi depletion 
of c-Myc upon serum deprivation
The above data demonstrated that knockdown of c-Myc in
MCF-7 cells could significantly inhibit the growth of tumor
cells both in vitro and in vivo. To determine whether deple-
tion of c-Myc could promote the death of tumor cells, flow
cytometry and TUNEL assays were performed. At 24 hours
after transfection with pSilencer–c-Myc or pSilencer, MCF-
7 cells were deprived of serum for 36 hours. These cells
were then analyzed by flow cytometry or TUNEL assay.
Significant sub-G1 (apoptotic) populations were observed
in the flow cytometry assay. We found that 31.1% of MCF-
7 cells transfected with pSilencer–c-Myc underwent apop-
tosis after serum starvation, compared with 5.8% in the
control group (Fig. 5a). We also confirmed the apoptosis of
MCF-7 cells by TUNEL assay (Fig. 5b). About 40% cells
were TUNEL-positive in the pSilencer–c-Myc group, com-
pared with 6% in the control group (P < 0.01). These data
suggested that depletion of c-Myc by RNAi in MCF-7 cells
made the cells more sensitive to apoptosis after serum
deprivation.
Discussion
Cancer cells often show alteration in the signal-transduc-
tion pathways, leading to proliferation in response to exter-
nal signals. Oncogene overexpression is a common
phenomenon in the development and progression of many
human cancers. Oncogenes therefore provide a potential
target for cancer gene therapy [13].
The important oncogene c-myc is expressed in a high pro-
portion of most human cancers, including breast, prostate,
gastrointestinal cancer, lymphoma, melanoma, and myeloid
leukemia [14]. In its physiological role, c-Myc is broadly
expressed during embryogenesis and in tissue compart-
ments of the adult that possess high proliferative capacity.
Altered expression of c-Myc seems to define a common
event associated with the pathogenesis of most human
cancers [6]. Previous studies demonstrated that the contin-
ued presence of c-Myc was required for cancer develop-
ment and not just for initiation, and inactivation of c-Myc
resulted in the sustained regression of tumors [15-17].
Similar results were also observed in breast cancer. D'Cruz
and colleagues demonstrated that overexpression of c-Myc
by an inducible system in the mammary epithelium of trans-
genic mice resulted in the formation of invasive mammary
adenocarcinomas, many of which regressed fully after c-
Myc deinduction [18].
Therefore, specific downregulation of c-Myc might be a
potential therapeutic strategy against human cancers,
including breast cancer. In fact, the antagonists of c-Myc,
including full-length antisense mRNA [19], oligonucle-
otides against c-myc mRNA [20] or a dominant-negative
mutant [21], were previously reported to inhibit proliferation
of cancer cell lines in vitro. However, it was only successful
in some situations; these technologies have been difficult
to apply universally [22]. Recently the advent of RNAi-
directed 'knock-down' has sparked a revolution in somatic
Figure 3
RNAi directed against c-Myc leads to a reduced cellular growth rate RNAi directed against c-Myc leads to a reduced cellular growth rate. 
MCF-7 cells were transfected with pSilencer–c-Myc or pSilencer. After 
48 hours the cells were trypsinized and replated at a density of 50 
cells/mm2 in triplicate. Cells were counted every 2 days. The data 
shown are means and SD from three independent experiments. **P < 
0.01.Breast Cancer Research    Vol 7 No 2    Wang et al.
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cell genetics, allowing the inexpensive, rapid analysis of
gene function in mammals, and might be exploited for gene
therapy [7,8]. Some studies directly compared RNAi with
antisense RNA and found that RNAi seemed to be quanti-
tatively more efficient and durable in cell culture and in
nude mice [23].
By means of the RNAi method, in the present study, cellular
growth assays, both in vitro and in vivo, were used to deter-
mine the functional consequences of RNAi-mediated
decreases in of c-Myc in established breast cancer cells.
Our results demonstrated that RNAi can effectively down-
regulate oncogene overexpression with great specificity.
We showed that the plasmids endogenously expressing
siRNA could successfully deplete up to 80% of c-Myc
expression in MCF-7 cells at day 5 after transfection. Fur-
thermore, the tumor inhibition effects persisted for at least
12 days after transfection in dishes and for 2 months in
nude mice as shown by experiments in vitro and in vivo,
even though the protein level of c-Myc in silenced clones
expressing siRNA was back to almost the same level as in
the control cells by day 12 after transfection. Our data were
consistent with the results of Jain and colleagues [17].
They showed that within 24 hours of c-myc inactivation, the
osteogenic sarcoma cells flattened and showed less cell
division. And even after reactivation of c-myc expression in
these cultured cells, total cell numbers continued to be
lower. Less than 1% of the tumor cells regained their
neoplastic growth properties [17]. All of these data indi-
cated that brief inactivation of c-Myc could induce a
sustained loss of neoplastic phenotypes. Moreover, other
groups using chemically synthesized siRNAs to knock
down their favored oncogenes also found that a transient
decrease in oncogene expression could inhibit the growth
of tumor cells in vitro and/or in vivo [8]. Nevertheless, the
underlying mechanism of this phenomenon in MCF-7 cells
should be further investigated.
Figure 4
Knockdown of c-Myc by RNAi reduces colony formation in soft agar Knockdown of c-Myc by RNAi reduces colony formation in soft agar. MCF-7 cells were transfected with pSilencer–c-Myc or pSilencer as controls, 
and seeded in 0.35% agarose containing Dulbecco's modified Eagle's medium with 10% fetal bovine serum. The colony numbers were counted 2 
weeks later. (a) Representative wells demonstrating the total number of colonies formed by MCF-7 transfected with the indicated plasmids. (b) The 
numbers of colonies of pSilencer–c-Myc-treated cells standardized against the control cells (set at 100%). The data shown are means and SD from 
two independent triplicate experiments. The difference between treatments is statistically significant (P < 0.001).
Table 1
RNAi directed against c-Myc significantly inhibits MCF-7 cell growth in nude mice
No. of cellsa pSilencer pSilencer–c-Myc
Tumor weight 
(mg)
Tumors Injections Latencyb (day) Tumor weight 
(mg)
Tumors Injections Latencyb 
(day)
106 45–210 3 5 42–49 0 0 5 >56
2 × 106 145–2248 4 5 21–28 0 0 5 >35
aNumber of cells transfected with the indicated plasmids that were injected subcutaneously, bilaterally into five nude mice.
bThe time interval required for a palpable tumor to arise.Available online http://breast-cancer-research.com/content/7/2/R220
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Although some studies previously revealed that the effects
of inactivation of c-Myc in some cell lines were modest [6],
other groups using different approaches to reduce the pro-
tein level of c-Myc found that a decrease in c-Myc expres-
sion could inhibit the growth of these tumor cells, including
breast tumor cells [19-21]. Nevertheless there were still
conflicting results on whether c-Myc expression was nec-
essary to maintain tumorigenesis in different animal models
from different laboratories [15-18,24,25]. For example,
some studies showed that the role of oncogenic c-Myc in
tumor maintenance was essential and that all effects of c-
Myc in vivo were reversible, in that without continuous c-
Myc activation there would even be regression of estab-
lished tumors back to phenotypically normal in transgenic
mouse models [15,16,24]. Similar phenomena were
observed by other groups focusing on other oncogenes,
such as bcr/abl [26] and H-ras [27]. However, there were
also conflicting reports, mainly showing that brief inactiva-
tion of c-Myc could induce sustained loss of neoplastic
phenotypes in certain animal models [17,18,25]. It was
notable that without secondary oncogenic mutation, spon-
taneously or selectively, such as Kras2 oncogene mutation,
in nearly all breast tumors induced by conditionally express-
ing the human c-Myc in the mammary epithelium of a trans-
genic mouse model, deinduction of c-Myc protein could
lead to full regression of tumors [18]. Similar data were also
obtained by Karlsson and colleagues that the inactivation of
c-Myc alone was found to be sufficient to cause sustained
tumor regression in c-Myc-induced hematopoietic tumors;
in contrast, tumor cells that acquired novel chromosomal
translocations relapsed independently of Myc to maintain
their neoplastic phenotype [25]. It was therefore not sur-
prising for us to show here that a transient reduction of c-
Myc protein level by RNAi could significantly inhibit the
growth rate of MCF-7 cells and its ability to form colonies
in soft agar. Additionally, the remarkable effect in nude mice
supported the effectiveness of this treatment.
Our data also suggested that knockdown of c-Myc by RNAi
in MCF-7 cells could increase the sensitivity of these cells
to apoptotic stimuli, such as serum starvation. This was
most probably one of the reasons for the anti-tumor effects.
There have previously been conflicting reports about the
role of c-Myc in apoptosis [3]. Constant overexpression of
c-Myc might induce apoptosis [2,6], and a decrease in c-
Myc levels by techniques brought about by, for example, an
antisense approach might also cause apoptosis of certain
tumor cells [28-30] or might increase the sensitivity of the
cells to apoptotic stimuli [31]. These conflicting observa-
tions suggested that c-Myc was capable of both inducing
and suppressing apoptosis in different types of tumor cell,
under different conditions, and in different systems. In
MCF-7 cells, suppression of c-Myc expression in response
to aromatase inhibitors or topoisomerase α inhibitors could
induce these cells to apoptosis [32,33]. However, the path-
ways that c-Myc controls and/or that are involved in the
observed apoptosis remain obscure. D'Agnano and col-
leagues suggested that in melanoma cells the downregula-
tion of c-Myc by an antisense approach could activate
apoptosis by increasing the levels of p27Kip1 [28]. Overex-
pression of the cyclin-dependent kinase inhibitor p27Kip1
was able to promote apoptosis in several mammalian tumor
cell lines [34]. However, understanding the precise path-
way by which a decrease in c-Myc in MCF-7 cells by RNAi
was able to induce apoptosis upon serum deprivation
needs further study.
So far, RNAi has been used to inhibit virus-induced dis-
eases (for example HIV [35] and influenza [36]), oncogenic
K-ras, H-ras-induced tumorigenesis [37,38], activation of
oncogenes resulting from chromosomal translocations (for
example bcr/abl in chromic myeloid leukemia [39]), can-
cers caused by viral infections [40], and so on. Recently,
retroviral-based approaches to deliver siRNA into tissue-
cultured mammalian cells have been proved to be powerful
[37,38], and doxycycline-regulated inducible knockdown of
gene expression by RNAi has been shown to be particularly
useful for the analysis of genes that are essential for cellular
survival [41,42]. These studies have marked a new era in
Figure 5
Apoptosis induced after serum deprivation by depletion of c-Myc in  MCF-7 cells Apoptosis induced after serum deprivation by depletion of c-Myc in 
MCF-7 cells. (a) Downregulation of c-Myc promoted apoptosis of 
MCF-7 cells after serum deprivation. MCF-7 cells were transfected with 
pSilencer–c-Myc or pSilencer. After 24 hours, cells were deprived of 
serum for 36 hours. Cells were then collected by trypsinization. The 
apoptotic cells were determined by flow cytometry. The cell population 
in sub-G1 is shown. The x and y axes show DNA content and cell 
number, respectively. (b) TUNEL assay to detect apoptotic cells in situ. 
MCF-7 cells were grown on coverslips and transfected with pSilencer–
c-Myc or pSilencer. After 24 hours, cells were deprived of serum for 36 
hours. Cells were then analyzed for apoptosis with the TUNEL assay. 
Dark-blue staining of nuclei indicates apoptosis. Arrows indicate repre-
sentative TUNEL-positive cells.Breast Cancer Research    Vol 7 No 2    Wang et al.
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the genetic manipulation of human cancer development by
allowing oncogenes to be downregulated by RNAi.
Conclusion
In summary, RNAi has been used in this study to demon-
strate that decreases in c-Myc levels can inhibit tumor
growth in assays both in vivo and in vitro. In addition, these
data indicate that RNAi provides a useful method with
which to study the role of genes that control the growth of
cancer cells; and, given its specificity and the lower doses
needed to inhibit gene expression than those required for
antisense oligonucleotides, RNAi might have potential ther-
apeutic utility in a variety of disease states, including can-
cers. Future studies could further test whether c-Myc
overexpression can be efficiently depleted by siRNA
expressed from a DNA-based expression vector combined
with a tumor-specific promoter, such that RNAi can specif-
ically target oncogenes in cancer cells without affecting
normal cells.
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